Drugs /

sargramostim

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.

Clinical Trials

View Clinical Trials for sargramostim

Sargramostim has been investigated in 23 clinical trials, of which 23 are open and 0 are closed. Of the trials investigating sargramostim, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 13 are phase 2 (13 open), 2 are phase 2/phase 3 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).

HER2 Deficient Expression, HER2 Negative, and HLA-A*02 Positive are the most frequent biomarker inclusion criteria for sargramostim clinical trials.

Neuroblastoma, breast carcinoma, and ganglioneuroblastoma are the most common diseases being investigated in sargramostim clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sargramostim
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sargramostim and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sargramostim, leukine, 23-l-leucinecolony-stimulating factor 2, sargramostim (substance), sargramostim, drg-0012, sargramostim [chemical/ingredient], sagramostim, sargramostim (product), prokine, rhu gm-cfs, colony-stimulating factor 2 (human clone phg25 protein moiety), 23-l-leucine-, gm-csf, sargramostatin
NCIT ID [1]:
C1492
SNOMED ID [1]:
C-5014E

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.